| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Sep―10 |
Pharmacokinetic and mass balance characterization of [
14
C] RAY1216, a SARS-CoV-2 M
pro
inhibitor, in healthy Chinese male subjects |
Wang Hu, Jiaxiang Ding, Yunqiu Xie, Tonghao Zhang, Yu Peng, Ying Wang, Xiaoni Wang, Peng Xu, Xiaoli Li, Xuefeng Wang, Heyue Wang, Ning Cheng, Jinmei Zhou, Luning Sun, Huan Zhou, Qi Qi |
| 2 |
[GO] |
2025―May―28 |
Magnolol inhibits viral replication and enhances antiviral immune responses against porcine reproductive and respiratory syndrome virus (PRRSV) in Marc-145 cells |
Shun Li, Mingzhan Zhu, Jingfei Deng, Yajuan Li, Yunfei Huang, Bikash R. Giri, Quan Liu, Qiang Fu |
| 3 |
[GO] |
2025―Mar―26 |
Functional foods and immune system: A sustainable inhibitory approach against SARS-COV-2 |
Hubza Ruatt Khan, Rabia Sultan, Mehvish Javeed, Humaira Yasmeen, Iqra Arooj, Sara Janiad |
| 4 |
[GO] |
2025―Feb―18 |
Nirmatrelvir treatment duration and frequency of COVID-19 rebound |
Nathan Sudeep, Noah Kojima, Jeffrey D Klausner |
| 5 |
[GO] |
2025―Jan―21 |
Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study |
Carsten S Larsen, Caroline L Westergaard, Nina B Stærke, Urs Arnet, Gui Liu, Line R Kantsø, Jakob Kjellberg |
| 6 |
[GO] |
2024―Dec―06 |
Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach |
Ahmed M Metwaly, Eslam B Elkaeed, Aisha A Alsfouk, Ibrahim M Ibrahim, Hazem Elkady, Ibrahim H Eissa |
| 7 |
[GO] |
2024―Jul―27 |
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort |
Courtney N. Nichols, Mark Lustberg, Mohammed Mahdee E Sobhanie, Lucia J Niermann, Melissa Gordon, Nicholas Kman, Jonathan Parsons, Mark Conroy, Michael Dick, James Allen, Erica Reed, Joy Lehman, Carlos Malvestutto |
| 8 |
[GO] |
2024―Jun―14 |
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study |
Qing Li, Hongmei Lu, Yongdui Ruan, Yuxuan Geng, Zuguo Zhao, Ying Liu, Long Feng, Wentao Guo |
| 9 |
[GO] |
2024―Feb―14 |
Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection |
Inès Boussen, Maud Salmona, Flore Sicre De Fontbrune, Aliénor Xhaard, Nathalie De Castro, Constance Delaugerre, Marie-Laure Chaix, Jean-Michel Molina |
| 10 |
[GO] |
2023―Oct―20 |
Subacute thyroiditis following COVID-19 vaccination: Case presentation |
Aleksandra Z Tomic, Sonja S Zafirovic, Zoran M Gluvic, Vladimir S Samardzic, Mirjana T Macvanin, Maja LJ Radunovic, Esma R Isenovic |
| 11 |
[GO] |
2023―Sep―06 |
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach |
Eslam B Elkaeed, Bshra A Alsfouk, Tuqa H Ibrahim, Reem K Arafa, Hazem Elkady, Ibrahim M Ibrahim, Ibrahim H Eissa, Ahmed M Metwaly |
| 12 |
[GO] |
2023―Jun―29 |
Letter to the editor on use of antibodies from convalescent sera in the treatment of moderate and severe Covid-19 infection |
Sarah B Nahhal, Bassem Awada, Joe-David Azzo, Rayyan Wazzi-Mkahal, Souha Kanj, Zeina A Kanafani |
| 13 |
[GO] |
2022―Dec―21 |
A favipiravir-induced angioedema and urticaria in a COVID-19 patient |
Figen Ergur Ozturk, Ayperi Ozturk, Hale Ates |
| 14 |
[GO] |
2022―Apr―14 |
Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus |
Bo-Jian Zheng, Yi Guan, Ming-Liang He, Hongzhe Sun, Lanying Du, Ying Zheng, Kin-Ling Wong, Honglin Chen, Ying Chen, Linyu Lu, Julian A Tanner, Rory M Watt, Neri Niccolai, Andrea Bernini, Ottavia Spiga, Patrick CY Woo, Hsiang-fu Kung, Kwok-Yung Yuen, Jian-Dong Huang |
| 15 |
[GO] |
2022―Apr―14 |
Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus |
Carla Amici, Antonino Di Caro, Alessandra Ciucci, Lucia Chiappa, Concetta Castilletti, Vito Martella, Nicola Decaro, Canio Buonavoglia, Maria R Capobianchi, M Gabriella Santoro |
| 16 |
[GO] |
2022―Apr―14 |
Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies |
Jens H Kuhn, Wenhui Li, Sheli R Radoshitzky, Hyeryun Choe, Michael Farzan |
| 17 |
[GO] |
2022―Apr―14 |
Protection of Mammalian Cells from Severe Acute Respiratory Syndrome Coronavirus Infection by Equine Neutralizing Antibody |
Xiliang Wang, Bing Ni, Xinan Du, Guangyu Zhao, Wenda Gao, Xinfu Shi, Songle Zhang, Liangyan Zhang, Dong Wang, Deyan Luo, Li Xing, Haiyan Jiang, Wanling Li, Man Jiang, Liwei Mao, Yangdong He, Yu Xiao, Yuzhang Wu |
| 18 |
[GO] |
2022―Apr―14 |
Probing the Structure of the Sars Coronavirus Using Scanning Electron Microscopy |
Yun Lin, Xiyun Yan, Wuchun Cao, Chaoying Wang, Jing Feng, Jinzhu Duan, Sishen Xie |
| 19 |
[GO] |
2022―Apr―14 |
Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine |
Jiang-Tao Lin, Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, Xin Chen, Yu-Xuan Liu, Hong Gao, Yu-Ping Jia, Yan Liu, Rui-Hua Sun, Xu Wang, Dong-Zheng Yu, Rong Hai, Qiang Gao, Ye Ning, Hong-Xia Wang, Ma-Chao Li, Biao Kan, Guan-Mu Dong, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Wei-Dong Yin, Xiao-Ping Dong |
| 20 |
[GO] |
2022―Apr―14 |
Inhibition of Replication and Infection of Severe Acute Respiratory Syndrome-Associated Coronavirus with Plasmid-Mediated Interference RNA |
Bing Ni, Xinfu Shi, Yang Li, Wenda Gao, Xiliang Wang, Yuzhang Wu |
| 21 |
[GO] |
2022―Apr―14 |
Human Coronaviruses: What Do They Cause? |
Lia Van Der Hoek |
| 22 |
[GO] |
2022―Apr―14 |
Neuraminidase Inhibitors and their Role in Avian and Pandemic Influenza |
Martin Crusat, Menno D De Jong |
| 23 |
[GO] |
2022―Apr―14 |
Discovery and Characterization of the 1918 Pandemic Influenza Virus in Historical Context |
Jeffery K Taubenberger, Johan V Hultin, David M Morens |
| 24 |
[GO] |
2022―Mar―07 |
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy |
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Maria Vittoria Mauro, Filippo Urso, Valeria Vangeli |
| 25 |
[GO] |
2022―Mar―02 |
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19 |
Tomas Cihlar, Richard L. Mackman |
| 26 |
[GO] |
2022―Feb―26 |
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study |
Alessandro F Chiesa, Micol Pallanza, Gladys Martinetti, Fabio Lanzi, Marco Previsdomini, Alberto Pagnamenta, Luigia Elzi |
| 27 |
[GO] |
2021―Oct―19 |
Real-life findings on the impact of the COVID-19 pandemic on HIV care |
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti, Simona Di Giambenedetto |
| 28 |
[GO] |
2021―Sep―02 |
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study |
Jeong Eun Lee, Soon Ok Lee, Jeonghun Heo, Dong Wan Kim, Mi Ran Park, Hyunjin Son, Dongkeun Kim, Kye-Hyung Kim, Shinwon Lee, Sun Hee Lee |
| 29 |
[GO] |
2021―Mar―11 |
The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review |
Jienchi Dorward, Oghenekome Gbinigie, Ting Cai, Nia W Roberts, Nigel Garrett, Gail Hayward, Christopher C Butler |
| 30 |
[GO] |
2021―Feb―22 |
COVID-19 and hepatitis B infection |
Saleh A Alqahtani, Maria Buti |
| 31 |
[GO] |
2021―Jan―18 |
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity |
Mattia Trunfio, Elena Salvador, Alberto Gaviraghi, Sabrina Audagnotto, Letizia Marinaro, Ilaria Motta, Riccardo Casciaro, Valeria Ghisetti, Carmen Fava, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno |
| 32 |
[GO] |
2020―Aug―03 |
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system |
Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, Graham Sewell, Andrew Hughes, Heinz Feldmann |
| 33 |
[GO] |
2020―Jun―26 |
SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection |
Elise J Smolders, Lindsey HM te Brake, David M Burger |
| 34 |
[GO] |
2020―Jun―04 |
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19 |
Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu |
|
